Duesseldorf

• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended recruitment
  2023-504331-41-00 5 2024-08-02 Respiratory tract diseases - Wheezing, Asthma
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended recruitment
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell … Ended recruitment
  2023-503594-38-00 1 2024-07-15 Select B-Cell malignancies.
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended recruitment
  2023-505722-33-00 4 2024-04-15 cholangiocarcinoma or gallbladder carcinoma
• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr … Ended recruitment
  2024-517959-12-00 9 2024-04-11 Relapsed/refractory B cell precursor acute lymphoblastic leukemia
• Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam … Ended recruitment
  2023-507448-36-00 5 2024-02-16 Non-small Cell Lung Cancer
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study of RZ358 in Patients with Congenital Hyperin … Ended recruitment
  2023-503240-13-00 5 2024-01-30 Hypoglycemia associated with congenital hyperinsulinism
• ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended recruitment
  2022-502110-85-00 5 2024-01-18 Peanut allergy
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• Study of safety, tolerability and efficacy of DFV890 in adult participants with myeloid diseases Ended recruitment
  2022-501406-36-00 3 2023-12-14 Myeloid disease
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E … Ended recruitment
  2023-506821-12-00 5 2023-10-12 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Me
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended recruitment
  2022-500430-29-00 5 2023-10-11 Myelodysplastic Syndrome (MDS)
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants with Systemic Lupus Er … Ended recruitment
  2022-502632-39-00 1 2023-10-11 Systemic Lupus Erythematosus (SLE)
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f … Ended recruitment
  2024-515224-37-00 4 2023-08-29 Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC in PD-L1 positive patients (CPS≥1) Ended recruitment
  2024-516536-10-00 4 2023-05-25 Locally advanced head and neck squamous cell carcinoma

Showing 217–240 of 383 trials